Management and Treatment of Perianal Fistulizing Crohn’s Disease

Joseph J Lee,1– 4 Amy L Lightner1,3,4 1Department of Colorectal Surgery, Scripps Clinic, La Jolla, CA, USA; 2Naval Medical Center San Diego, Department of Surgery, San Diego, CA, USA; 3Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA, USA; 4Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USACorrespondence: Amy L Lightner, Email [email protected]: Perianal fistulizing Crohn’s disease is a severe and disabling phenotype of Crohn’s disease, affecting up to one-third of Crohn’s patients. This phenotype can result in significant quality of life impairment in quality of life due to chronic pain, persistent perianal drainage, and the risk of fecal incontinence. The presence of a perianal fistula indicates a more aggressive disease course, often requiring more frequent and coordinated care. Optimal management relies on a multidisciplinary team, including gastroenterologists, colorectal surgeons, and radiologists, to address the complex interplay of medical and surgical needs. Medical therapy achieves durable remission in only about one-third of patients, necessitating surgical intervention for the majority, with patients arriving to the operating room with more advanced disease activity and longer duration of immunosuppression. For patients with refractory disease, mesenchymal stem cell (MSC) therapy has emerged as a promising option, with clinical remission rates of approximately 50– 80% at 6– 12 months and a favorable safety profile, notably without increasing the risk of incontinence compared to conventional surgery. However, there is no approved MSC product currently available for clinical use. Given the complexity and morbidity of fistulizing perianal Crohn’s disease, a multidisciplinary approach focused on individualized, evidence-based therapy is essential for optimizing outcomes.Keywords: perianal Crohn’s disease, perianal fistula, mesenchymal stem cell therapy, perianal surgery

Publication Details

Journal
Dove Medical Press (Taylor and Francis Group)
Published
2025-12-13
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management and Treatment of Perianal Fistulizing Crohn’s Disease

Dove Medical Press (Taylor and Francis Group)
Inflammatory Bowel Disease
article

Management and Treatment of Perianal Fistulizing Crohn’s Disease

article en

Abstract

Joseph J Lee,1– 4 Amy L Lightner1,3,4 1Department of Colorectal Surgery, Scripps Clinic, La Jolla, CA, USA; 2Naval Medical Center San Diego, Department of Surgery, San Diego, CA, USA; 3Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, CA, USA; 4Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USACorrespondence: Amy L Lightner, Email [email protected]: Perianal fistulizing Crohn’s disease is a severe and disabling phenotype of Crohn’s disease, affecting up to one-third of Crohn’s patients. This phenotype can result in significant quality of life impairment in quality of life due to chronic pain, persistent perianal drainage, and the risk of fecal incontinence. The presence of a perianal fistula indicates a more aggressive disease course, often requiring more frequent and coordinated care. Optimal management relies on a multidisciplinary team, including gastroenterologists, colorectal surgeons, and radiologists, to address the complex interplay of medical and surgical needs. Medical therapy achieves durable remission in only about one-third of patients, necessitating surgical intervention for the majority, with patients arriving to the operating room with more advanced disease activity and longer duration of immunosuppression. For patients with refractory disease, mesenchymal stem cell (MSC) therapy has emerged as a promising option, with clinical remission rates of approximately 50– 80% at 6– 12 months and a favorable safety profile, notably without increasing the risk of incontinence compared to conventional surgery. However, there is no approved MSC product currently available for clinical use. Given the complexity and morbidity of fistulizing perianal Crohn’s disease, a multidisciplinary approach focused on individualized, evidence-based therapy is essential for optimizing outcomes.Keywords: perianal Crohn’s disease, perianal fistula, mesenchymal stem cell therapy, perianal surgery

Dove Medical Press (Taylor and Francis Group)
Openalex Percentile: Top 27%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.